Lantheus Stock Downgraded, Price Target Offers Upside Despite Challenges

Lantheus Holdings' stock (NASDAQ: LNTH) is dealing with some analyst cuts, primarily stemming from performance concerns surrounding its key product, Pylarify. Recent downgrades, including one this morning, have impacted market sentiment, yet price target estimations continue to suggest a potential upside for the pharmaceutical company.

The stock is currently trading 2.6% lower in the pre-market session this morning. This price action reflects the market's response to a series of revised outlooks from prominent financial institutions. The current price reflects investor apprehension as the company addresses headwinds.

Goldman Sachs downgraded Lantheus to “Neutral” from “Buy” today, setting a price target of $77, a reduction from the previous $110. The firm's analysis points to modest risks in achieving consensus sales estimates over the intermediate term. Goldman Sachs suggests that a recovery in share value hinges on Lantheus demonstrating clearer visibility into its organic growth prospects. Factors contributing to this revised outlook include pricing pressure affecting Pylarify, slower than anticipated adoption rates for approved Alzheimer's disease therapeutics, and recent acquisitions that have introduced complexity in predicting the company's future growth trajectory. The firm views the current risk/reward profile of the stock as balanced.

Prior to this, Truist Securities also downgraded Lantheus, moving to a “Hold” rating from “Buy” on August 11, 2025, and lowering the price target from $111 to $63. This decision was similarly driven by concerns regarding Pylarify's performance, with expectations of potential stagnation for approximately six months. Truist however, acknowledged the long-term pipeline which remains underappreciated, anticipating double-digit revenue and earnings growth beginning in late 2026 through 2027 and beyond.

These downgrades followed an earlier price target reduction by Goldman Sachs on August 7, from $140 to $110, while maintaining a “Buy” rating at the time. This adjustment came after Lantheus reported a second-quarter revenue miss and subsequently reduced its fiscal year 2025 guidance by 10%.

The underperformance of Pylarify, impacted by pricing pressures, was a significant factor in this revision. Despite these challenges, Goldman Sachs expressed optimism regarding Lantheus's longer-term opportunities, particularly with pipeline products expected to launch in 2026, including next-generation PET imaging and Alzheimer's-related offerings.